A Pilot Study to Evaluate the Efficacy of GFT505 (80mg) Orally Administered Once Daily for 8 Weeks on Insulin Sensitivity Using a Glucose Clamp Technique and Safety in Male Patients With Insulin Resistance and Abdominal Obesity. A Multicentre, Randomised, Single Blind, Placebo-Controlled, Cross Over Study
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Elafibranor (Primary)
- Indications Insulin resistance; Obesity; Prediabetic state
- Focus Therapeutic Use
- Sponsors Genfit
- 30 May 2013 Results published in Diabetes Care, according to a GENFIT media release.
- 27 May 2013 A combined analysis of four phase IIa studies was published in Hepatology, according to a GENFIT media release.
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.